Article
Oncology
Pasquale Rescigno, Bora Gurel, Rita Pereira, Mateus Crespo, Jan Rekowski, Mattia Rediti, Maialen Barrero, Joaquin Mateo, Diletta Bianchini, Carlo Messina, Maria D. Fenor de la Maza, Khobe Chandran, Juliet Carmichael, Christina Guo, Alec Paschalis, Adam Sharp, George Seed, Ines Figueiredo, Maryou Lambros, Susana Miranda, Ana Ferreira, Claudia Bertan, Ruth Riisnaes, Nuria Porta, Wei Yuan, Suzanne Carreira, Johann S. de Bono
Summary: Patients with CDK12-altered mCRPC have a worse prognosis, and their tumors are primarily enriched for CD4(+)FOXP3(-) cells, which may be associated with poor outcomes and immunosuppression.
CLINICAL CANCER RESEARCH
(2021)
Editorial Material
Oncology
Tamara L. Lotan, Emmanuel S. Antonarakis
Summary: CDK12 inactivation in prostate cancer may generate fusion-associated neoantigens and elicit immune responses. The T-cell immune microenvironment of CDK12-deficient prostate cancers showed an increase in immunosuppressive CD4(+) FOXP3(-) T cells compared to CDK12-proficient controls.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Elizabeth Pan, Angelo Cabal, Juan Javier-DesLoges, Devin Patel, Justine Panian, Suzanna Lee, Justin Shaya, Taylor Nonato, Xiaojun Xu, Tyler Stewart, Brent Rose, Ahmed Shabaik, Ezra Cohen, Razelle Kurzrock, Pablo Tamayo, Rana R. McKay
Summary: CDK12 alterations are rare events across hematologic and solid tumor malignancies. They represent a clinically distinct molecular cancer subtype which may have increased responsiveness to checkpoint inhibition. Prospective studies are warranted to investigate checkpoint inhibition in CDK12-altered tumors.
Article
Oncology
Enrico Moiso, Paolo Provero
Summary: This study systematically investigates the associations between metabolic alterations and other tumor features using a comprehensive collection of data. The results provide a guide for formulating specific mechanistic hypotheses and contribute to our understanding of the role of metabolic alterations in cancer and the development of precision therapeutic strategies.
Article
Multidisciplinary Sciences
Kaiyue Zhou, Suzan Arslanturk, Douglas B. Craig, Elisabeth Heath, Sorin Draghici
Summary: Prostate cancer is the second leading cause of cancer death in American men, and over-diagnosis and over-treatment of low-risk patients can have significant long-term effects on quality of life. Cross-cancer disease learning helps discover important biomarkers, enriches study populations, and identifies important commonalities across diseases.
SCIENTIFIC REPORTS
(2021)
Article
Multidisciplinary Sciences
Leigh Anne Stout, Nawal Kassem, Cynthia Hunter, Santosh Philips, Milan Radovich, Bryan P. Schneider
Summary: Next-generation sequencing of ctDNA can help guide therapy selection for cancer patients, but caution should be taken when interpreting variants with a VAF between 40-60%, as these may indicate germline status. VAF in ctDNA is a useful predictor for germline variant carriage, but should not be used as a sole indicator for germline testing.
SCIENTIFIC REPORTS
(2021)
Article
Cell Biology
Hanqi Lei, Zifeng Wang, Donggen Jiang, Fang Liu, Meiling Liu, Xinxing Lei, Yafei Yang, Bin He, Min Yan, Hai Huang, Quentin Liu, Jun Pang
Summary: The study identified CDK12 as a critical factor for PCa cell survival, and its inhibition by THZ531 led to anti-PCa effects. THZ531 downregulated AR signaling and selectively repressed a distinct class of transcripts, affecting cellular survival. CDK12 inhibition was also linked to the sensitivity of PCa cells to apoptosis pathways and potential oncogenes.
CELL DEATH & DISEASE
(2021)
Review
Urology & Nephrology
Irene Casanova-Salas, Alejandro Athie, Paul C. Boutros, Marzia Del Re, David T. Miyamoto, Kenneth J. Pienta, Edwin M. Posadas, Adam G. Sowalsky, Arnulf Stenzl, Alexander W. Wyatt, Joaquin Mateo
Summary: Liquid biopsy has emerged as a practical tool to profile tumor dynamics over time, elucidating features that evolve with tumor progression. Blood-based liquid biopsies have demonstrated promise as prognostic and response biomarkers in both localized tumors and advanced disease.
Article
Oncology
Wenjian Zhang, Lushan Zhou, Jianzhong Di
Summary: This meta-analysis investigates the role of CDK12 mutation in prostate cancer. The analysis shows that CDK12 mutation is associated with poor prognosis in prostate cancer patients and is correlated with high-grade Gleason scores. Therefore, CDK12 can be used as a biomarker for molecular subtype and a potential therapeutic target of prostate cancer.
EXPERT REVIEW OF ANTICANCER THERAPY
(2023)
Article
Oncology
Evan Warner, Cameron Herberts, Simon Fu, Steven Yip, Amanda Wong, Gang Wang, Elie Ritch, Andrew J. Murtha, Gillian Vandekerkhove, Nicolette M. Fonseca, Arkhjamil Angeles, Arshia Beigi, Elena Schonlau, Kevin Beja, Matti Annala, Daniel Khalaf, Kim N. Chi, Alexander W. Wyatt
Summary: The study identifies BRCA2, ATM, and CDK12 as the most frequently disrupted DDR genes in ctDNA of metastatic prostate cancer patients, collectively mutated in 15% of cases. ATM defects and TP53 mutations were rare, with most patients showing biallelic gene disruption. Loss of BRCA2 and CDK12, but not ATM, was associated with poor clinical outcomes.
CLINICAL CANCER RESEARCH
(2021)
Review
Endocrinology & Metabolism
Andrea K. K. Miyahira, Jessica E. E. Hawley, Remi Adelaiye-Ogala, Jeremie Calais, Lucia Nappi, Ravi Parikh, Tyler M. M. Seibert, Elizabeth V. V. Wasmuth, Xiao X. X. Wei, Kenneth J. J. Pienta, Howard R. R. Soule
Summary: This article provides an overview of the 2022 Coffey-Holden Prostate Cancer Academy Meeting, highlighting the major topic areas discussed and summarizing the scientific presentations. The goal is to disseminate this knowledge and contribute to the advancement of global prostate cancer research efforts.
Article
Oncology
Christopher Gaffney, Deli Liu, Victoria Cooley, Xiayoue Ma, Cynthia Angulo, Brian Robinson, Francesca Khani, Peter Cai, Simpa Salami, Srinivas Nallandhighal, Jonathan Shoag, Christopher Barbieri
Summary: The study shows that prostate tumor size is associated with aggressive tumor biology and genomic risk, independently correlated with gene expression and genomic risk markers. Tumors of different sizes exhibit distinct gene expression patterns and enrichment of different gene sets, suggesting the potential significance of tumor size in future assessment of cancer aggressiveness.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
(2021)
Article
Oncology
Cankun Zhou, Chaomei Li, Yuhua Zheng, Xiaobin Huang
Summary: This study comprehensively elucidated the expression levels, prognostic efficiency, potential biological functions, genomic and epigenetic characteristics, immune microenvironment, and drug sensitivity of cuproptosis regulators in pan-cancer.
FRONTIERS IN ONCOLOGY
(2022)
Review
Endocrinology & Metabolism
Andrea K. Miyahira, Jelani C. Zarif, Catherine C. Coombs, Robert R. Flavell, Joshua W. Russo, Samir Zaidi, Di Zhao, Shuang G. Zhao, Kenneth J. Pienta, Howard R. Soule
Summary: The 2021 CHPCA Meeting focused on critical topics in prostate cancer research, including cancer genomics, signaling pathways in metastatic castration resistant prostate cancer, immune responses to cancer, and imaging the tumor microenvironment. The meeting aimed to accelerate understanding and development of new biomarkers and treatments for prostate cancer through sharing of research findings.
Article
Medical Laboratory Technology
Kenneth Chappell, Bruno Francou, Christophe Habib, Thomas Huby, Marco Leoni, Aurelien Cottin, Florian Nadal, Eric Adnet, Eric Paoli, Christophe Oliveira, Celine Verstuyft, Anne Davit-Spraul, Pauline Gaignard, Elise Lebigot, Jean-Charles Duclos-Vallee, Jacques Young, Peter Kamenicky, David Adams, Andoni Echaniz-Laguna, Emmanuel Gonzales, Claire Bouvattier, Agnes Linglart, Veronique Picard, Emilie Bergoin, Emmanuel Jacquemin, Anne Guiochon-Mantel, Alexis Proust, Jerome Bouligand
Summary: This study reports 5 years of experience in using the Galaxy platform for high-throughput sequencing data analysis in a clinical laboratory setting. The results demonstrate that Galaxy is a suitable platform with great potential to benefit patient care in a clinical laboratory setting.
CLINICAL CHEMISTRY
(2022)
Article
Urology & Nephrology
Anna Plym, Yiwen Zhang, Konrad H. Stopsack, Benedicte Delcoigne, Fredrik Wiklund, Christopher Haiman, Stacey A. Kenfield, Adam S. Kibel, Edward Giovannucci, Kathryn L. Penney, Lorelei A. Mucci
Summary: This study aims to examine whether adherence to a healthy lifestyle can reduce the risk of disease or disease progression in men at an increased genetic risk of prostate cancer. In a prospective study, it was found that high-risk men who adhered to a healthy lifestyle had a lower probability of developing fatal prostate cancer.
Article
Oncology
Charles W. Ashley, Pier Selenica, Juber Patel, Michelle Wu, Josip Nincevic, Yulia Lakhman, Qin Zhou, Ronak H. Shah, Michael F. Berger, Arnaud Da Cruz Paula, David N. Brown, Antonio Marra, Alexia Iasonos, Amir Momeni-Boroujeni, Kaled M. Alektiar, Kara Long Roche, Oliver Zivanovic, Jennifer J. Mueller, Dmitriy Zamarin, Vance A. Broach, Yukio Sonoda, Mario M. Leitao Jr, Claire F. Friedman, Elizabeth Jewell, Jorge S. Reis-Filho, Lora H. Ellenson, Carol Aghajanian, Nadeem R. Abu-Rustum, Karen Cadoo, Britta Weigelt
Summary: Sequencing analysis of circulating cell-free DNA in endometrial cancer patients can capture the mutational repertoire of the primary lesion and allow for disease monitoring.
CLINICAL CANCER RESEARCH
(2023)
Article
Urology & Nephrology
Ethan S. Barnett, Nikolaus Schultz, Konrad H. Stopsack, Ernest T. Lam, Andrea Arfe, Jerry Lee, Jimmy L. Zhao, Joseph D. Schonhoft, Emily A. Carbone, Niamh M. Keegan, Andreas Wibmer, Yipeng Wang, David B. Solit, Wassim Abida, Richard Wenstrup, Howard I. Scher
Summary: Single-cell, shallow whole-genome sequencing (CTC sWGS) is a more effective method for detecting BRCA2 loss in patients with metastatic castration-resistant prostate cancer (mCRPC) compared to tissue biopsies.
Article
Biochemistry & Molecular Biology
Anqi Wang, Yili Xu, Yao Yu, Kevin T. Nead, TaeBeom Kim, Keren Xu, Tokhir Dadaev, Ed Saunders, Xin Sheng, Peggy Wan, Loreall Pooler, Lucy Y. Xia, Stephen Chanock, Sonja Berndt, Susan M. Gapstur, Victoria Stevens, Demetrius Albanes, Stephanie J. Weinstein, Vincent Gnanapragasam, Graham G. Giles, Tu Nguyen-Dumont, Roger L. Milne, Mark M. Pomerantz, Julie A. Schmidt, Konrad H. Stopsack, Lorelei A. Mucci, William J. Catalona, Kurt N. Hetrick, Kimberly F. Doheny, Robert J. MacInnis, Melissa C. Southey, Rosalind A. Eeles, Fredrik Wiklund, Zsofia Kote-Jarai, Adam J. de Smith, David Conti, Chad Huff, Christopher A. Haiman, Burcu F. Darst
Summary: This study found that clonal hematopoiesis of indeterminate potential (CHIP) was not significantly associated with the risk of prostate cancer. Although CHIP was weakly associated with genetic risk of overall prostate cancer, there was no significant association with genes related to aggressive prostate cancer.
HUMAN MOLECULAR GENETICS
(2023)
Article
Oncology
Konrad H. Stopsack, Xiaofeng A. Su, J. Bailey Vaselkiv, Rebecca E. Graff, Ericka M. Ebot, Andreas Pettersson, Rosina T. Lis, Michelangelo Fiorentino, Massimo Loda, Kathryn L. Penney, Tamara L. Lotan, Lorelei A. Mucci
Summary: The most common event in primary prostate cancer is the fusion between TMPRSS2 and ERG genes. Non-ERG ETS fusions in tumors show genomic similarity with ERG fusions, particularly in the regulation of metabolic pathways.
MOLECULAR CANCER RESEARCH
(2023)
Editorial Material
Oncology
Christina E. Henson, Daniel J. Morton, Jyoti S. Mayadev, Stuart J. Wong, Dmitriy Zamarin
Article
Oncology
Ying L. Liu, Dmitriy Zamarin
CLINICAL CANCER RESEARCH
(2023)
Article
Oncology
Maria M. Rubinstein, Eric Rios Doria, Jason Konner, Stuart Lichtman, Qin Zhou, Alexia Iasonos, Debra Sarasohn, Tiffany Troso-Sandoval, Claire Friedman, Roisin O'Cearbhaill, Karen Cadoo, Chrisann Kyi, Seth Cohen, Krysten Soldan, Eric Billinson, Imogen Caird, Dasom Jang, Khalil Eid, Pooja Shah, Joyce Guillen, Carol Aghajanian, Dmitriy Zamarin, Vicky Makker
Summary: This study examined the efficacy of single-agent immune checkpoint blockade and combination immune checkpoint blockade in patients with endometrial cancer. The results showed limited response to immune checkpoint blockade in these patients, indicating the need for further research into potential mechanisms of resistance to immunotherapy in endometrial cancer.
GYNECOLOGIC ONCOLOGY
(2023)
Article
Oncology
Hari S. Iyer, Kevin H. Kensler, Jane B. Vaselkiv, Konrad H. Stopsack, Charlotte Roscoe, Elisa V. Bandera, Bo Qin, Thomas L. Jang, Tamara L. Lotan, Peter James, Jaime E. Hart, Lorelei A. Mucci, Francine Laden, Timothy R. Rebbeck
Summary: There is growing evidence that unfavorable neighborhood contexts may influence prostate cancer progression. However, it is unclear whether these associations can be partially explained by differences in tumor-level somatic alterations.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
(2023)
Editorial Material
Oncology
Konrad H. Stopsack, Anna Plym, Lorelei A. Mucci
Summary: Metastases are the main cause of morbidity and mortality from solid tumors. However, current cancer registries only capture data on metastatic cancers diagnosed at the time of diagnosis, missing the recurrent metastases of previously nonmetastatic tumors. This study estimates that about half of all metastatic cancers in prostate cancer arise as recurrences from initially nonmetastatic disease. Therefore, establishing a database that includes all incident metastatic cancer cases, regardless of initial stage, is crucial for better understanding the disparities in metastatic disease burden and the effectiveness of prevention, screening, and therapies for primary and metastatic disease.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
(2023)
Article
Oncology
Kimberly Dessources, Lorenzo Ferrando, Qin C. Zhou, Alexia Iasonos, Nadeem R. Abu-Rustum, Jorge S. Reis-Filho, Nadeem Riaz, Dmitriy Zamarin, Britta Weigelt
Summary: This explorative study investigated the relationship between molecular subtypes and immune features of endometrial cancer. The CD8+ cell infiltration in CN-high subtype was associated with improved prognosis, while it was not prognostic in MSI-high and CN-low subtypes. Additionally, POLE-mutated and MSI-high subtypes exhibited immunosuppressive characteristics. Different molecular subtypes of endometrial cancer have unique immune resistance mechanisms.
GYNECOLOGIC ONCOLOGY
(2023)
Article
Oncology
Beryl L. Manning-Geist, Sacha Gnjatic, Carol Aghajanian, Jason Konner, Sarah H. Kim, Debra Sarasohn, Krysten Soldan, William P. Tew, Nicholas J. Sarlis, Dmitriy Zamarin, Sara Kravetz, Ilaria Laface, Teresa Rasalan-Ho, Jingjing Qi, Phillip Wong, Paul J. Sabbatini, Roisin E. O'Cearbhaill
Summary: A combination therapy of WT1 peptide vaccine and nivolumab has been found to induce immune responses in ovarian cancer patients, and it is safe and tolerable. This study provides additional evidence for the combination of immune checkpoint inhibitors and vaccines.
Article
Oncology
Xiaoshuang Feng, Yiwen Zhang, J. Bailey Vaselkiv, Ruifeng Li, Paul L. Nguyen, Kathryn L. Penney, Edward L. Giovannucci, Lorelei A. Mucci, Konrad H. Stopsack
Summary: The study found that modifiable risk factors for future prostate cancer among men with a negative biopsy were generally consistent with those for the general population. Higher BMI and lower alcohol intake tended to be associated with lower rates of localised disease, while coffee, lycopene intake, and statin use tended to be associated with lower rates of lethal prostate cancer.
BRITISH JOURNAL OF CANCER
(2023)
Article
Oncology
Chaoran Ma, Xiaoyu Wang, James Y. Dai, Constance Turman, Peter Kraft, Konrad H. Stopsack, Massimo Loda, Andreas Pettersson, Lorelei A. Mucci, Janet L. Stanford, Kathryn L. Penney
Summary: This study investigated the germline genetic variants associated with TMPRSS2:ERG fusion status in prostate cancer cases. The findings suggest that tumors with TMPRSS2:ERG fusion have a different genetic etiology compared to fusion negative cases. The study identified several SNPs at known prostate cancer risk loci that were differentially associated with the risk of developing prostate tumors with or without the gene fusion.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
(2023)
Letter
Oncology
Konrad H. Stopsack, Lorelei A. Mucci, Edward L. Giovannucci
JOURNAL OF CLINICAL ONCOLOGY
(2023)